RxCelerate Overview
- Founded
-
2013
- Status
-
Private
- Employees
-
80
- Latest Deal Type
-
Early Stage VC
- Investors
-
1
RxCelerate General Information
Description
Operator of an outsourced drug discovery and development platform intended to specialize in non-clinical models of diseases. The company's platform offers bespoke efficacy models, including a study design that combines efficacy and toxicology end-points in a single study wrapper and specializes in bespoke experimental design with data-rich endpoints, enabling researchers to improve the productivity of drug discovery and development.
Contact Information
Website
www.rxcelerate.com
Formerly Known As
Tcp Biotech
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Healthcare Services
Other Pharmaceuticals and Biotechnology
Primary Office
- B950 Dorothy Hodgkin Building
- Babraham Research Campus, Babraham
- Cambridge CB22 3FH
- England, United Kingdom
+44 01223 000000
RxCelerate Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 01-Jan-2015 | Completed | Generating Revenue |
RxCelerate Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
RxCelerate Patents
RxCelerate Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202219662-D0 | Reagents for building to a binding site | Pending | 23-Dec-2022 |
RxCelerate Executive Team (5)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Jill Reckless Ph.D | Co-Founder, Board Member & Chief Executive Officer | ||
| Elaine McKilligin Ph.D | Board Member & Company Secretary | ||
| Nicholas Tait | Chief Financial Officer & Board Member | ||
| David Grainger Ph.D | Co-Founder & Executive Chairman |
RxCelerate Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| David Grainger Ph.D | Self | Co-Founder & Executive Chairman | 000 0000 |
| Elaine McKilligin Ph.D | RxCelerate | Board Member & Company Secretary | 000 0000 |
| Jill Reckless Ph.D | RxCelerate | Co-Founder, Board Member & Chief Executive Officer | 000 0000 |
| Nicholas Tait | Self | Chief Financial Officer & Board Member | 000 0000 |
RxCelerate Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
RxCelerate Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Total Medical Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |
RxCelerate Investments & Acquisitions (6)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000 00 | 22-Nov-2022 | 0000000000 | Drug Discovery | 0000 0000 | |
| 00000 0000000 | 22-Sep-2022 | 00000 0000 | 00000 | Drug Discovery | |
| 00000 0000000 | 20-Jul-2021 | 00000 0000 | 0000 | Drug Discovery | |
| 00000000 | 05-Feb-2019 | 0000000000 | Other Pharmaceuticals and Biotechnology | 00000 000 | |
| The Cambridge Partnership | 08-May-2018 | Merger/Acquisition | 00.000 | Accounting, Audit and Tax Services (B2B) | 0000 0000 |
RxCelerate Subsidiaries (4)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Methuselah Health | Drug Discovery | Cambridge, United Kingdom | 2014 |
| 000 000000000 0000 | Accounting, Audit and Tax Services (B2B) | Cambridge, United Kingdom | 0000 |
| 00000000 | Other Pharmaceuticals and Biotechnology | Cambridge, United Kingdom | 0000 |
| 00000 0000000000 | Biotechnology | Cambridge, United Kingdom | 0000 |